![](/images/Email.png)
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Akebia Therapeutics
US Patent
Akebia Therapeutics
US Patent
Affinity DataEC50: 9.90E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)